-
Product Insights
Medullary Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Medullary Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Medullary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dabrafenib Mesylate in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Hairy Cell Leukemia Drug Details: Dabrafenib...
-
Product Insights
NewNet Present Value Model: United Therapeutics Corp’s Ralinepag
Empower your strategies with our Net Present Value Model: United Therapeutics Corp's Ralinepag report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-001 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KB-001 in Alzheimer's Disease Drug Details: KB-001 is under development for the treatment of Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VTP-200 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-200 in Cervical CancerDrug Details:VTP-200 is under development for the treatment of HPV associated cervical cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zastaprazan in Corrosive Esophagitis (Erosive Esophagitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zastaprazan in Corrosive Esophagitis (Erosive Esophagitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zastaprazan in Corrosive Esophagitis (Erosive Esophagitis) Drug Details: Zastaprazan is under...